Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
SVRA
SVRA
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
SVRA News
Savara Receives FDA Day 74 Letter, MOLBREEVI Progressing Smoothly
4d ago
Newsfilter
SAVARA INC AIMS TO FILE MAA WITH UK MHRA BY END OF Q1 2026
4d ago
moomoo
Savara Seeks FDA Approval for Molbreevi to Treat Rare Lung Disease
Feb 21 2026
stocktwits
FDA Grants Priority Review for Savara's Molbreevi BLA Resubmission
Feb 20 2026
seekingalpha
Savara Receives FDA Priority Review for MOLBREEVI BLA Submission
Feb 20 2026
Businesswire
Savara Receives Priority Review for MOLBREEVI, Potential First Therapy for Autoimmune PAP
Feb 20 2026
Newsfilter
Savara Secures $150M Non-Dilutive Capital for MOLBREEVI Launch
Jan 27 2026
Newsfilter
Savara (SVRA) Faces Class Action Lawsuit Over Shareholder Losses
Jan 24 2026
Globenewswire
Savara Submits MOLBREEVI BLA for Autoimmune PAP Treatment, Targeting FDA Approval
Jan 08 2026
Newsfilter
Galectin Secures $10M Credit Line, FDA Provides Guidance on Regulatory Pathway
Dec 26 2025
NASDAQ.COM
Savara Resubmits MOLBREEVI BLA with Fujifilm as Manufacturer, Requests Priority Review
Dec 26 2025
Newsfilter
BofA Raises ArcBest Price Target to $84 Amid Neutral Rating
Dec 23 2025
Benzinga
Savara Resubmits MOLBREEVI Application to FDA Seeking Priority Review
Dec 23 2025
NASDAQ.COM
Savara Refiles MOLBREEVI BLA with FDA, Requests Priority Review
Dec 22 2025
SeekingAlpha
Savara Inc. to Present MOLBREEVI Progress at 44th J.P. Morgan Healthcare Conference
Dec 17 2025
Newsfilter
Savara Secures European Patent for MOLBREEVI Until March 2041
Dec 11 2025
Newsfilter
Show More News
